Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olatorepatide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Olatorepatide arm 1 | EXPERIMENTAL | - |
| Olatorepatide arm 2 | EXPERIMENTAL | - |
| Olatorepatide arm 3 | EXPERIMENTAL | - |
| Olatorepatide arm 4 | EXPERIMENTAL | - |
| Olatorepatide arm 5 | EXPERIMENTAL | - |
| Matching Placebo arm 6 | ACTIVE_COMPARATOR | - |
| General Cohort | EXPERIMENTAL | - |
| Subgroup Cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Olatorepatide | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary...
Olatorepatide is an investigational small molecule being developed for the treatment of overweight or obesity. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in adult participants living with overweight or obesity, including those without diabetes.
Olatorepatide is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting Phase 2 clinical trials to evaluate the drug's safety and efficacy in adults with overweight or obesity.
Olatorepatide is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. Two Phase 2 trials are ongoing, one active but not recruiting and one currently recruiting participants.
Olatorepatide is being studied in two Phase 2 clinical trials. The first, NCT07431086, is a study in adult participants with overweight or obesity in the US, with 120 participants enrolled. The second, NCT07685808, is a study in adults with overweight or obesity without diabetes, with 360 participants. Both are randomized, double-blind, and controlled.
Olatorepatide is a peptide-based small molecule, classified under the -tide (peptide) target class. It is being investigated for its potential to treat overweight or obesity, though its specific molecular target has not been disclosed. The drug is administered as a small molecule and is currently in Phase 2 trials.